An ACR Convergence 2022 session provided practical updates on ways to best protect pediatric & adult patients with rheumatic disease from COVID-19.
Search results for: hospital
Patients Living with Chronic Illness
At ACR Convergence 2022, three women with rheumatic diseases discuss the profound life changes that the diseases wrought and ways they’ve found to cope.
Clinical Rheumatology Year in Review—2022
In this overview of clinical updates in rheumatology in the last year, high-impact studies were discussed, including the GLORIA, ORAL Surveillance and MIRROR trials.
A Shot of Wisdom: Vaccinations in Patients with Rheumatic Disease
PHILADELPHIA—The treatment of rheumatic diseases is often a double-edged sword: immunosuppressive regimens can be very effective in reducing disease activity, but the cost of such treatments may be seen in the form of increased risk of infection. At ACR Convergence 2022, the session titled ACR Guidelines for Vaccination in Patients with Rheumatic and Musculoskeletal Diseases…
Patients Fight Against Dark Days & Find Ways to Cope
PHILADELPHIA—Amy Gietzen started feeling the pain when she was 19. Her forearms, elbows, wrists and fingers were constantly swollen and sensitive. Six months later, she saw a doctor and was diagnosed with systemic diffuse scleroderma—a particularly hard-to-manage rheumatic disease with wide-ranging effects. Ms. Gietzen, who spoke at ACR Convergence 2022 and is a public speaker,…
Evolution of Medicare’s Merit-Based Incentive Payment System: MIPS Value Pathways
In November, the CMS finalized 12 MIPS Value Pathways (MVP) in the Quality Payment Program, including a rheumatology MVP. In 2023, clinicians can opt to report via traditional MIPS, the rheumatology MVP or both.
New Findings for Polymyalgia Rheumatica & Osteoarthritis
The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.
Challenges in Psoriatic Arthritis
PHILADELPHIA—Despite a large and ever-growing number of therapeutic options for our patients with psoriatic disease, it is not uncommon for us come across scenarios in which a patient’s response to therapy does not match our expectations and our shared goals for treatment. We all have those patients—the ones whose joints improve with one drug, but…
Phase 2 Trial Results for Sjögren’s Syndrome & SLE Presented in 2nd Plenary Session at ACR Convergence 2022
PHILADELPHIA—At the second Plenary Session of ACR Convergence on Sunday, Nov. 13, speakers shared compelling efficacy and safety results from two phase 2 trials: remibrutinib for Sjögren’s syndrome and deucravacitinib for moderate to severe systemic lupus erythematosus. Remibrutinib in Phase 2 Sjögren’s Syndrome Trial Thomas Dörner, MD, a professor of rheumatology and clinical immunology for…
Gout Research at a Glance
PHILADELPHIA—Approximately 60 research abstracts on gout were accepted for presentation at ACR Convergence 2022, including two plenary abstract presentations. It is exciting to see a wealth of research on gout being undertaken worldwide. Here, we highlight important points from seven of these studies. 1. Abstract 1810: Frequency and Patterns of Opioid Use in the Management…
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 323
- Next Page »